ASCO 2015 Highlights

C. Daniel Mullins, PhD, talks about the importance of considering the value equation when it comes to treating oncology patients. Oncologists should have conversations with their patients about clinical effectiveness and affordability in order to determine the best course of treatment. This approach is more challenging, but leads to more patient-centered care.

Dr. Bosserman explains that in her practice, patients want to be involved in their care. They want the truth about their disease, treatment, outcomes, and cost, and they want to hear it from their doctor.

Oncologists should be guided by the research that is being done around outcomes, benefit, and society impact when making value-based care decisions, says Dr. Stainthorpe.

Dr. Stainthorpe shares his belief that when it comes to care decisions, oncology patients should be provided with information about the benefits/outcomes/consequences and cost of their care.

Dr. Stainthorpe emphasizes that oncologists should focus their efforts on treating the patient in a way that will produce the fewest side effects and greatest chance of survival. However, there may be times when cost should factor into the equation.

When it comes to copays, cancer patients shoulder an unfair burden compared with other disease states. Dr. Bosserman talks about this need for a solution and the idea that a true, value-based system would help to make care more affordable for patients.

Increasing costs of copays are causing oncologists, such as Dr. Bosserman, to learn and understand more about the options (both coverage and treatment) available to patients.

Dr. Stainthorpe explains that the single payer perspective allows for negotiated terms and equality of access; however, they do not necessarily drive down costs the way multiple payers can.

Dr. Mullins confirms that value in healthcare is incredibly important to both patients and insurance companies. The development of many new treatment options in the field of oncology makes it a prime place to look for value. Value can be determined by comparing evidence of cost and evidence of improved health outcomes.